GLP-1类似物对急性ST段抬高型心肌梗死预后的临床研究

Abstract
Figure/Table
References (19)
Related Citation (2)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo observe the efficacy and safety of Liraglutide in PCI treatment for patients with ST-elevation acute myocardial infarction.Methods160 new patients with STEMI given emergency PCI accompanying with high blood glucose on admission treated in our hospital from January 2014 to November 2016 were selected and they were randomly divided into the experimental group(n=80)and control group(n=80).In the experimental group,Liraglutide was used as soon as possible after being selected to intervene the blood glucose,while in the control group,other methods were used to intervene the blood glucose.The glycosylated hemoglobin,left ventricular end diastolic diameter and left ventricular ejection fraction were observed and compared between the two groups after 7,30 and 90 d operation;the incidence rate of major cardiovascular events(MACE)including possible or definite ventricular fibrillation,cardiac death,recurrent angina,acute left heart attack,and revascularization between two groups were compared.ResultsThe left ventricular end diastolic diameter and left ventricular ejection fraction in the observation group after 30 and 90 d operation were better than those in the control group (P＜0.05).There was 1 case of cardiac death in two groups,and it can be thought as ardiac rupture,and the observation group of 5 cases underwent revascularization,7 cases in the control group were scheduled for non infarct relatedartery revascularization,and incidence rate of MACE between two group showed no significant difference(P＞0.05).ConclusionBased on AMI conventional direct PCI and drug treatment,Liraglutide added to conduct blood glucose intervening can improve the left ventricular remodeling recently and increase the ejection fraction of left ventricle.

Key words： Liraglutide ST-elevation acute myocardial infarction Emergency percutaneous coronary intervention

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Hui
	DENG Gen-qun
	ZHENG Xiao-qun

Cite this article:

ZHANG Hui,DENG Gen-qun,ZHENG Xiao-qun. Clinical study of glucagon-like peptide-1 in the prognosis of patients with ST-elevationacute myocardial infarction[J]. 中国当代医药, 2017, 24(16): 48-50转57.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I16/48

[1]	朱禧星.现代糖尿病学[M].上海：上海医科大学出版社，2000.
[2]	Oswald GA，Smith CC，Betteridge DJ，et al.Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction[J].Br Med J （Clin Res Ed），1986，293（6552）：917-922.
[3]	Ravid M，Berkowicz M，Sohar E.Hyperglycemia during acute myocardial infarction[J].JAMA，1975，233（7）：807-809.
[9]	Ceriello A.Acute hyperglycaemia：a'new'risk factor during myocardial infarction[J].Eur Heart J，2005，26（4）：328-331.
[4]	Lynch M，Gammage MD，Lamb P，et al.Acute myocardial infarction in diabetic patients in the thrombolytic era[J].Diabet Med，1994，11（2）：162-165.
[5]	Soler NG，Frank S.Value of glycosylated hemoglobin measurements after acute myocardial infarction[J].JAMA，1981，246（15）：1690-1693.
[6]	Bellodi G，Manicardi V，Malavasi V，et al.Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus[J].Am J Cardiol，1989，64（14）：885-888.
[7]	Sewdarsen M，Vythilingum S，Jialal I，et al.Prognostic importance of admission plasma glucose in diabetic and non-diabetic patients with acute myocardial infarction[J].Q J Med，1989，71（265）：461-466.
[8]	O′Sullivan JJ，Conroy RM，Robinson K，et al.In-hospital prognosis of patients with fasting hyperglycemia after first myocardial infarction[J].Diabetes Care，1991，14（8）：758-760.
[10]	Gwilt DJ，Petri M，Lamb P，et al.Effect of intravenous insulin infusion on mortality among diabetic patients after myocardial infarction[J].Heart，1984，51（6）：626-630.
[11]	WeihrauchD，LohrNL，MraovicB，etal.Chronichyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin[J].Circulation，2004，109（19）：2343-2348.
[12]	Teraguchi I，Imanishi T，Ozaki Y，et al.Acute-phase glucose fluctuation is negatively correlated with myocardial salvage after acute myocardial infarction[J].Circ J，2014，78（1）：170-179.
[13]	Salehi M，Aulinger BA，D′Alessio DA.Targeting β -Cell Mass in Type 2 Diabetes：Promise and Limitations of New Drugs Based on Incretins[J].Endocr Rev，2008，29（3）：367-379.
[14]	Egom EE.A therapeutic approach to hyperglycaemia in the settingofacutemyocardialinfarction：spotlighton glucagonlike peptide 1[J].Ther Adv Cardiovasc Dis，2012，6（5）：213-219.
[15]	Houtgraaf JH，De JR，Monkhorst K，et al.Feasibility of intracoronary GLP-1 eluting CellBeadTMinfusion in acute myocardial infarction[J].Cell Transplant，2013，22（3）：535-543.
[16]	Grieve DJ，Cassidy RS，Green BD.Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1：potential therapeutic benefits beyond glycaemic control?[J].Br J Pharmacol，2009，157（8）：1340-1351.
[17]	NikolaidisLA，MankadS，SokosGG，etal.Effectsofglucagonlikepeptide-1inpatientswithacutemyocardialinfarctionand left ventricular dysfunction after successful reperfusion[J].Circulation，2004，109（8）：962-965.
[18]	Read PA，Hoole SP，White PA，et al.A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemicdysfunctionandattenuatesstunningaftercoronaryballoon occlusion in humans[J].Circ Cardiovasc Interv，2011，4（3）：266-272.
[19]	Chen WR，Hu SY，Chen YD，et al.Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].Am Heart J，2015，170（5）：845-854.